|
|
 |
|
Viewing report
|
|
|
|
Lupin Generics Company Intelligence Report
Espicom Business Intelligence Ltd, Jan 2011, Pages: 16
Lupin's roots stretch back to 1968, with its formulations commercialised in 1976. In 1981, Lupin began ethambutol production, becoming one of the largest producers in
the world. In 1991, Lupin began cephalosporin production.
Lupin's first ANDA to be approved by the US FDA was cefuorxime axetil, which gained approval in 2003. In 2004, Lupin introduced its first brand to the US: Suprax, a
cefixime product that had previously been marketed by Wyeth until March 2003.
The firm's products are available in nearly 70 countries, with its overseas business accounting for around 65% of total revenues.
For the year ended 31st March 2010, Lupin announced consolidated sales worth Rs47,678.4 million (US$1,006.5 million). This was an increase of 24.7% over the prior
year. Net profit rose by 35.9% to Rs6,816.3 million (US$143.9 million).
Executive Summary
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Customers who bought this item also bought
Lupin Limited - Product Pipeline Review - 2012
Lupin Limited - Product Pipeline Review - H2 2011
Lupin Limited - Product Pipeline Review - Q4 2010
Aurobindo Generics Company Intelligence Report
Ranbaxy Generics Company Intelligence Report
Dr Reddy's Laboratories Generics Company Intelligence Report
Cipla Generics Company Intelligence Report
Aspen Pharmacare Generics Company Intelligence Report
Wockhardt Generics Company Intelligence Report
Zydus Cadila Generics Company Intelligence Report
|
|
|
|
